Any feedback?
Literature summary for 3.4.24.75 extracted from
- Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin (2007), J. Antimicrob. Chemother., 59, 759-762.
Natural Substrates/ Products (Substrates)
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| additional information | Staphylococcus simulans | potent, synergistic inhibition of Staphylococcus aureus strains MSSA476 and MRSA252 upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin, which is most potent, as well as with the antimicrobial peptides magainin 2 and dermaseptin s3(1-16), overview | ? | - |
? |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Staphylococcus simulans | - |
- |
- |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| additional information | potent, synergistic inhibition of Staphylococcus aureus strains MSSA476 and MRSA252 upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin, which is most potent, as well as with the antimicrobial peptides magainin 2 and dermaseptin s3(1-16), overview | Staphylococcus simulans | ? | - |
? | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
